Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Advanced Solid Malignancy, × capivasertib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 17 Prostatic Neoplasms 6 Triple Negative Breast Neoplasms 5 Neoplasm Metastasis 4 Recurrence 2 Ovarian Neoplasms 2 Neoplasms 2 Melanoma 2 Leukemia 2 Healthy Participants 2 Endometrial Neoplasms 2 Disease Progression 2 Uterine Cervical Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumour 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1 Non-small Cell Lung Cancer Metastatic 1 Moderate Hepatic Impairment 1 Metastatic Castration-resistant Prostate Cancer (mCRPC) 1 Meningioma 1 Lymphoma, Mantle-Cell 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma, B-Cell 1 Lymphoma 1 Lung Neoplasms 1 Hereditary Sensory and Autonomic Neuropathies 1 Hematologic Neoplasms 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01895946 2016-05-25

OAK

AstraZeneca

Phase 1 Completed

33 enrolled 14 charts

Advanced Solid Malignancy,

Data powered by HemOnc (CC BY 4.0) Colophon ⚡